Search

Your search keyword '"Goldsmith, Scott R."' showing total 169 results
Start Over Author "Goldsmith, Scott R."
169 results on '"Goldsmith, Scott R."'

2. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author

Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.

Published
2022

3. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

7. Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration.

Author

Goldsmith, Scott R., San-Rozano, May, Katindoy, Justine, Rattanapichetkul, Janet, and Rosenzweig, Michael

Subjects
HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, STEM cell treatment, MULTIPLE myeloma, NON-Hodgkin's lymphoma
Abstract

High-dose chemotherapy with autologous hematopoietic cell transplantation (AutoHCT) has long been an integral treatment modality for multiple myeloma and non-Hodgkin lymphoma. Over the past 25 years, numerous institutions have shifted this practice from requiring hospitalization to one that can be performed in an ambulatory setting, resulting in cost savings and improved quality of life for patients. The recent advent immune-effector cell (IEC) therapies and expansion of their indications is changing the treatment landscape for hematologic and non-hematologic malignancies. However, current financial models and reimbursement structures threaten the viability and sustainability of this treatment modality should it continue to require inpatient administration and management. This threat is leading institutions to develop outpatient IEC programs based off the outpatient AutoHCT templates. Integral to the success of both is a cohesive program with outpatient-specific standard operating protocols, highly-trained providers and staff with expertise specific in these treatment modalities, evidenced-based supportive care and prophylaxis plans, extensive caregiver vetting and education, and the infrastructure to support all individuals involved. In this policy and practice review we provide an overview of the guidelines and published academic experiences, give a perspective-based description of the roles and responsibilities of the individuals involved in this process at our institution, and highlight actionable recommendations that could allow for the dissemination and implementation of outpatient AutoHCT and IEC programs more broadly. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

Author

Goldsmith, Scott R., Shouse, Geoffrey, Wong, F. Lennie, Bosworth, Alysia, Iukuridze, Aleksi, Chen, Sitong, Rhee, June-Wha, Mei, Matthew, Htut, Myo, Janakiram, Murali, Forman, Stephen J., Pillai, Raju, Budde, L Elizabeth, and Armenian, Saro H.

Abstract

•Clonal hematopoiesis (CH) is frequent in patients with non-Hodgkin lymphoma and multiple myeloma.•Pre-CAR T CH was associated with a higher incidence of severe cytokine release syndrome (CRS).•Clonal hematopoiesis could serve as a predictive biomarker for prevention strategies for CRS.

Published
2024
Full Text
View/download PDF

11. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial

Author

Goldsmith, Scott R, primary, Covut, Fahrettin, additional, Fiala, Mark, additional, Xiang, Zhifu, additional, Iqbal, Zahid, additional, Moore, Nathan, additional, Bradtke, Elizabeth, additional, Christen, Brandon, additional, Rettig, Michael P, additional, Christ, Stephanie, additional, Gehrs, Leah, additional, Street, Emily, additional, Wallace, Nicholas, additional, Ritchey, Julie, additional, Gao, Feng, additional, Pachter, Jonathan, additional, Parikh, Bijal, additional, Dubberke, Erik R, additional, and DiPersio, John F, additional

Published
2023
Full Text
View/download PDF

12. Co-evolution of tumor and immune cells during progression of multiple myeloma

Author

Liu, Ruiyang, Gao, Qingsong, Foltz, Steven M., Fowles, Jared S., Yao, Lijun, Wang, Julia Tianjiao, Cao, Song, Sun, Hua, Wendl, Michael C., Sethuraman, Sunantha, Weerasinghe, Amila, Rettig, Michael P., Storrs, Erik P., Yoon, Christopher J., Wyczalkowski, Matthew A., McMichael, Joshua F., Kohnen, Daniel R., King, Justin, Goldsmith, Scott R., O’Neal, Julie, Fulton, Robert S., Fronick, Catrina C., Ley, Timothy J., Jayasinghe, Reyka G., Fiala, Mark A., Oh, Stephen T., DiPersio, John F., Vij, Ravi, and Ding, Li

Published
2021
Full Text
View/download PDF

16. P-018 Prior BCMA-directed bispecific antibody or CAR T is not associated with increased risk of early infections in patients treated with bispecific antibodies

Author

Liu, Lawrence, primary, Goldsmith, Scott R., additional, Leahey, Sheryl, additional, Gomez, Carlos, additional, Streeter, Shawn, additional, Braun, Adam, additional, Htut, Myo, additional, Nathwani, Nitya, additional, Rosenzweig, Michael, additional, Sahebi, Firoozeh, additional, Borogovac, Azra, additional, Chowdhury, Arnab, additional, Dadwal, Sanjeet, additional, Krishnan, Amrita, additional, and Janakiram, Murali, additional

Published
2023
Full Text
View/download PDF

17. Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Author

Yao, Lijun, primary, Wang, Julia T., primary, Jayasinghe, Reyka G., primary, O'Neal, Julie, primary, Tsai, Chia-Feng, primary, Rettig, Michael P., primary, Song, Yizhe, primary, Liu, Ruiyang, primary, Zhao, Yanyan, primary, Ibrahim, Omar M., primary, Fiala, Mark A., primary, Fortier, Julie M., primary, Chen, Siqi, primary, Gehrs, Leah, primary, Rodrigues, Fernanda Martins, primary, Wendl, Michael C., primary, Kohnen, Daniel, primary, Shinkle, Andrew, primary, Cao, Song, primary, Foltz, Steven M., primary, Zhou, Daniel Cui, primary, Storrs, Erik, primary, Wyczalkowski, Matthew A., primary, Mani, Smrithi, primary, Goldsmith, Scott R., primary, Zhu, Ying, primary, Hamilton, Mark, primary, Liu, Tao, primary, Chen, Feng, primary, Vij, Ravi, primary, Ding, Li, primary, and DiPersio, John F., primary

Published
2023
Full Text
View/download PDF

18. Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Author

Yao, Lijun, primary, Wang, Julia T., primary, Jayasinghe, Reyka G., primary, O'Neal, Julie, primary, Tsai, Chia-Feng, primary, Rettig, Michael P., primary, Song, Yizhe, primary, Liu, Ruiyang, primary, Zhao, Yanyan, primary, Ibrahim, Omar M., primary, Fiala, Mark A., primary, Fortier, Julie M., primary, Chen, Siqi, primary, Gehrs, Leah, primary, Rodrigues, Fernanda Martins, primary, Wendl, Michael C., primary, Kohnen, Daniel, primary, Shinkle, Andrew, primary, Cao, Song, primary, Foltz, Steven M., primary, Zhou, Daniel Cui, primary, Storrs, Erik, primary, Wyczalkowski, Matthew A., primary, Mani, Smrithi, primary, Goldsmith, Scott R., primary, Zhu, Ying, primary, Hamilton, Mark, primary, Liu, Tao, primary, Chen, Feng, primary, Vij, Ravi, primary, Ding, Li, primary, and DiPersio, John F., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Author

Yao, Lijun, primary, Wang, Julia T., primary, Jayasinghe, Reyka G., primary, O'Neal, Julie, primary, Tsai, Chia-Feng, primary, Rettig, Michael P., primary, Song, Yizhe, primary, Liu, Ruiyang, primary, Zhao, Yanyan, primary, Ibrahim, Omar M., primary, Fiala, Mark A., primary, Fortier, Julie M., primary, Chen, Siqi, primary, Gehrs, Leah, primary, Rodrigues, Fernanda Martins, primary, Wendl, Michael C., primary, Kohnen, Daniel, primary, Shinkle, Andrew, primary, Cao, Song, primary, Foltz, Steven M., primary, Zhou, Daniel Cui, primary, Storrs, Erik, primary, Wyczalkowski, Matthew A., primary, Mani, Smrithi, primary, Goldsmith, Scott R., primary, Zhu, Ying, primary, Hamilton, Mark, primary, Liu, Tao, primary, Chen, Feng, primary, Vij, Ravi, primary, Ding, Li, primary, and DiPersio, John F., primary

Published
2023
Full Text
View/download PDF

20. A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma

Author

Sawalha, Yazeed, primary, Goyal, Subir, additional, Switchenko, Jeffrey M., additional, Romancik, Jason T., additional, Kamdar, Manali, additional, Greenwell, Irl Brian, additional, Hess, Brian T., additional, Isaac, Krista M., additional, Portell, Craig A., additional, Mejia Garcia, Alex V., additional, Goldsmith, Scott R, additional, Grover, Natalie S., additional, Riedell, Peter A., additional, Karmali, Reem, additional, Burkart, Madelyn, additional, Buege, Michael, additional, Akhtar, Othman S., additional, Torka, Pallawi, additional, Kumar, Anita, additional, Hill, Brian T., additional, Kahl, Brad S., additional, and Cohen, Jonathon B., additional

Published
2023
Full Text
View/download PDF

21. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

Author

Yao, Lijun, primary, Wang, Julia T., additional, Jayasinghe, Reyka G., additional, O'Neal, Julie, additional, Tsai, Chia-Feng, additional, Rettig, Michael P., additional, Song, Yizhe, additional, Liu, Ruiyang, additional, Zhao, Yanyan, additional, Ibrahim, Omar M., additional, Fiala, Mark A., additional, Fortier, Julie M., additional, Chen, Siqi, additional, Gehrs, Leah, additional, Rodrigues, Fernanda Martins, additional, Wendl, Michael C., additional, Kohnen, Daniel, additional, Shinkle, Andrew, additional, Cao, Song, additional, Foltz, Steven M., additional, Zhou, Daniel Cui, additional, Storrs, Erik, additional, Wyczalkowski, Matthew A., additional, Mani, Smrithi, additional, Goldsmith, Scott R., additional, Zhu, Ying, additional, Hamilton, Mark, additional, Liu, Tao, additional, Chen, Feng, additional, Vij, Ravi, additional, Ding, Li, additional, and DiPersio, John F., additional

Published
2023
Full Text
View/download PDF

23. Duvelisib for Critically-Ill Patients with COVID-19 Disease: An Investigator-Initiated, Randomized, Placebo-Controlled Double-Blind Pilot Trial

Author

Goldsmith, Scott R., primary, Covut, Fahrettin, additional, Fiala, Mark A., additional, Bradtke, Elizabeth, additional, Gasanli, Ayan, additional, Christen, Brandon, additional, Pachter, Jonathan A., additional, Xiang, Zhifu, additional, Iqbal, Zahid, additional, Moore, Nathan, additional, Ofoma, Uchenna, additional, Parikh, Bijal, additional, Dubberke, Erik, additional, and DiPersio, John F., additional

Published
2022
Full Text
View/download PDF

28. Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis

Author

Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, Irl Brian, Hess, Brian T., Isaac, Krista, Portell, Craig A., Mejia Garcia, Alex V., Goldsmith, Scott R., Grover, Natalie S, Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael J, Akhtar, Othman S., Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., and Cohen, Jonathon B.

Published
2020
Full Text
View/download PDF

29. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Author

Goldsmith, Scott R., primary, Abid, Muhammad Bilal, additional, Auletta, Jeffery J., additional, Bashey, Asad, additional, Beitinjaneh, Amer, additional, Castillo, Paul, additional, Chemaly, Roy F., additional, Chen, Min, additional, Ciurea, Stefan, additional, Dandoy, Christopher E., additional, Díaz, Miguel Ángel, additional, Fuchs, Ephraim, additional, Ganguly, Siddhartha, additional, Kanakry, Christopher G., additional, Kanakry, Jennifer A., additional, Kim, Soyoung, additional, Komanduri, Krishna V., additional, Krem, Maxwell M., additional, Lazarus, Hillard M., additional, Liu, Hongtao, additional, Ljungman, Per, additional, Masiarz, Richard, additional, Mulroney, Carolyn, additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Page, Kristin M., additional, Perales, Miguel-Angel, additional, Taplitz, Randy, additional, Romee, Rizwan, additional, and Riches, Marcie, additional

Published
2021
Full Text
View/download PDF

31. Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Author

Yao, Lijun, primary, Jayasinghe, Reyka G, additional, Wang, Tianjiao, additional, O'Neal, Julie, additional, Liu, Ruiyang, additional, Rettig, Michael P., additional, Tsai, Chia-Feng, additional, Foltz, Steven M., additional, Kohnen, Danny, additional, Mani, Smrithi, additional, Martins Rodrigues, Fernanda, additional, Wendl, Michael C., additional, Wyczalkowski, Matthew A., additional, Goldsmith, Scott R., additional, Zhu, Ying, additional, Fiala, Mark A, additional, Tao, Liu, additional, Vij, Ravi, additional, Ding, Li, additional, and DiPersio, John F., additional

Published
2020
Full Text
View/download PDF

34. Incidence and Impact of Non-CMV Herpes Viral Infection in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

Author

Singh, Anurag K., primary, Fuchs, Ephraim J., additional, Bashey, Asad, additional, Ciurea, Stefan O., additional, Goldsmith, Scott R., additional, Ganguly, Siddhartha, additional, Taplitz, Randy, additional, Mulroney, Carolyn, additional, Maziarz, Richard T., additional, Kim, Soyoung, additional, Chen, Min, additional, Chemaly, Roy F., additional, Komanduri, Krishna V., additional, Perales, Miguel, additional, Romee, Rizwan, additional, and Riches, Marcie L., additional

Published
2020
Full Text
View/download PDF

35. Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

Author

Goldsmith, Scott R, primary, Fuchs, Ephraim J., additional, Bashey, Asad, additional, Ciurea, Stefan O., additional, Singh, Anurag K, additional, Ganguly, Siddhartha, additional, Taplitz, Randy, additional, Mulroney, Carolyn, additional, Maziarz, Richard T., additional, Kim, Soyoung, additional, Chen, Min, additional, Chemaly, Roy F., additional, Komanduri, Krishna V., additional, Perales, Miguel, additional, Romee, Rizwan, additional, and Riches, Marcie L., additional

Published
2020
Full Text
View/download PDF

36. Incidence and Impact of Community Respiratory Viral Infection (CRV) in Haploidentical and Matched Sibling Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

Author

Taplitz, Randy, primary, Maziarz, Richard T., additional, Mulroney, Carolyn, additional, Perales, Miguel, additional, Romee, Rizwan, additional, Goldsmith, Scott R., additional, Fuchs, Ephraim J., additional, Bashey, Asad, additional, Ciurea, Stefan O., additional, Singh, Anurag K, additional, Ganguly, Siddhartha, additional, Kim, Soyoung, additional, Chen, Min, additional, Chemaly, Roy F., additional, Komanduri, Krishna V., additional, and Riches, Marcie L., additional

Published
2020
Full Text
View/download PDF

38. Single-Cell Transcriptomic and Proteomic Diversity in Multiple Myeloma

Author

Jayasinghe, Reyka G, primary, Wu, Yige, additional, Zhu, Ying, additional, Liu, Ruiyang, additional, Fiala, Mark A., additional, Kohnen, Daniel R., additional, Tsai, Chia-Feng, additional, Mani, Smrithi, additional, King, Justin, additional, Rettig, Michael P., additional, O'Neal, Julie, additional, Wang, Tianjiao, additional, Foltz, Steven M., additional, Yao, Lijun, additional, Sun, Hua, additional, Fronick, Catrina, additional, Goldsmith, Scott R., additional, DiPersio, John F., additional, Vij, Ravi, additional, Tao, Liu, additional, and Ding, Li, additional

Published
2019
Full Text
View/download PDF

44. Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Author

Goldsmith, Scott R., Shouse, Geoffrey P., Wong, F. Lennie, Bosworth, Alysia, Iujuridze, Aleksi, Chen, Sitong, Rhee, June-Wha, Mei, Matthew G., Janakiram, Murali, Htut, Myo, Forman, Stephen J., Pillai, Raju, Budde, L. Elizabeth, and Armenian, Saro

Abstract

Background:Among patients receiving CD19 or B-cell maturation antigen (BCMA) CAR-T therapy, inflammation pre- and post-CAR-T infusion is attributed in the development of toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and prolonged cytopenias. Clonal hematopoiesis (CH), the clonal expansion of hematopoietic stem cells with somatic mutations, has been associated with inflammatory disorders such as rheumatoid arthritis and graft-versus-host disease, as well as clonal cytopenias of undetermined significance. In the setting of CAR-T, others have reported an association between CH and both ICANS and treatment-associated myeloid neoplasms. Herein, we examined the prevalence of pre-CAR-T CH in a predominantly transplant-naïve cohort of recipients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), and assessed the relationship between CH and CAR-T related outcomes including CRS, ICANS, prolonged cytopenia, progression-free survival (PFS), and overall survival (OS).

Published
2023
Full Text
View/download PDF

45. Impact of Health Insurance and Access to Autologous Stem Cell Transplantation (ASCT) on Racial Inequity in Overall Survival (OS) Among Patients with Multiple Myeloma (MM)

Author

Wong, F. Lennie, Goldsmith, Scott R., Ashing, Kimlin, Krishnan, Amrita, Rosenzweig, Michael, and Armenian, Saro

Abstract

Background:Survival for patients with MM has improved in the past two decades, largely attributed to the advent of novel therapies and increased use of autologous stem cell transplantation (ASCT). However, questions remain whether African Americans/Blacks (AAs) have benefitted equally from survival improvement compared to whites. Few studies have examined the simultaneous impact of health system inequities ( i.e.insurance, access to ASCT) on differential outcomes by race. We addressed these knowledge gaps using the real-world data of the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database.

Published
2023
Full Text
View/download PDF

46. Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Author

Moloudizargari, Milad, Dona, Ada Alice, Park, Miso, Tandoh, Theophilus, Murtadha, Mariam, Caserta, Enrico, Pozhitkov, Alexander, Zhu, Yinghui, Napolitano, Ottavio, Sanchez, James, Nigam, Lokesh, Duplan, Amanda, Chowdhury, Arnab, Ghoda, Lucy Y., Keats, Jonathan, Goldsmith, Scott R., Rosenzweig, Michael, Krishnan, Amrita, Williams, John C., and Pichiorri, Flavia

Abstract

The use of immune checkpoint inhibitors has markedly improved the survival outcomes of many patients with solid tumors. However, in multiple myeloma (MM), the use of such inhibitors has failed to achieve survival benefit. We previously showed that oncolytic herpes simplex virus 1 (oHSV-1) can effectively infect MM cells and induce apoptosis through the receptors for oHSV-1, NECTIN-1 and HVEM (herpes virus entry mediator). HVEM, a member of the TNF receptor superfamily (TNFRSF14), is an immune checkpoint present on T cells, B cells, NK cells and macrophages. Depending on HVEM's interaction with its major inhibitory ligand, B- and T-lymphocyte attenuator (BTLA) or its major activating ligand, tumor necrosis factor superfamily member 14 (TNFSF14, LIGHT), it is pivotal in downmodulating or stimulating the immune cells. Accordingly, targeting HVEM to block its interaction with BTLA is an area of therapeutic interest.

Published
2023
Full Text
View/download PDF

47. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

Author

Goldsmith, Scott R., primary, Slade, Michael, additional, DiPersio, John F., additional, Westervelt, Peter, additional, Lawrence, Steven J., additional, Uy, Geoffrey L., additional, Abboud, Camille N., additional, Vij, Ravi, additional, Schroeder, Mark A., additional, Fehniger, Todd A., additional, Dubberke, Erik R., additional, Trinkaus, Kathryn, additional, and Romee, Rizwan, additional

Published
2016
Full Text
View/download PDF

48. Comparable Survival with HLA Haploidentical and Mismatched Unrelated Donor Transplants in Patients with AML and MDS

Author

Bansal, Dhruv, primary, Slade, Michael, additional, Manjappa, Shivaprasad, additional, Goldsmith, Scott R., additional, DiPersio, John F., additional, Westervelt, Peter, additional, Uy, Geoffrey L., additional, Vij, Ravi, additional, Abboud, Camille, additional, Stockerl-Goldstein, Keith, additional, Trinkaus, Kathryn, additional, and Romee, Rizwan, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results